Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Filippo de Marinis"'
Autor:
Konstantin Laktionov, Chong-Jen Yu, Kye Young Lee, Frances A. Shepherd, Roy S. Herbst, Filippo de Marinis, Yi-Long Wu, Zhijie Wang, Jonathan W. Goldman, Charuwan Akewanlop, Christian Grohé, Terufumi Kato, Thomas John, Huu Vinh Vu, Margarita Majem, Laura Bonanno, Ajlan Atasoy, Masahiro Tsuboi, Lingmin Zeng, Sang-We Kim, Shun Lu, Manuel Domine
Publikováno v:
Journal of Thoracic Oncology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Introduction: Adjuvant chemotherapy is recommended in patients with resected stages II to IIIA (and select IB) NSCLC; however, recurrence rates are high. In the phase 3 ADAURA study (NCT02511106), osimertinib was found to have a clinically meaningful
Autor:
Filippo de Marinis, Francesca Porta, Elena Guerini-Rocco, Carmine Valenza, Giuseppe Curigliano, Chiara Catania, Alessandra Rappa, Massimo Barberis, Giuseppe Viale
Publikováno v:
Current Oncology, Vol 28, Iss 292, Pp 3384-3392 (2021)
Current Oncology
Current Oncology
We present a case of a woman with epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma who received gefitinib for 2 years and obtained a partial response. The patient then developed liver metastasis and a breast lesion, displaying high
Autor:
Yi-Long Wu, Ying Cheng, Jianying Zhou, Shun Lu, Yiping Zhang, Jun Zhao, Dong-Wan Kim, Ross Andrew Soo, Sang-We Kim, Hongming Pan, Yuh-Min Chen, Chih-Feng Chian, Xiaoqing Liu, Daniel Shao Weng Tan, Rolf Bruns, Josef Straub, Andreas Johne, Jürgen Scheele, Keunchil Park, James Chih-Hsin Yang, Zhe Liu, Xi Chen, Mengzhao Wang, Shiying Yu, Helong Zhang, Jian Fang, Wei Li, Chih-Hsin Yang, Gee-Chen Chang, Te-Chun Hsia, Cheng-Ta Yang, Chin-Chou Wang, Byoung Chul Cho, Ki Hyeong Lee, Young-Chul Kim, Ho Jung An, In Sook Woo, Jae Yong Cho, Sang Won Shin, Jong-Seok Lee, Joo-Hang Kim, Seung Soo Yoo, Terufumi Kato, Naofumi Shinagawa, Shao Weng Daniel Tan, Lynette Si-Mien Ngo, Kananathan Ratnavelu, Azura Rozila Ahmad, Chong Kin Liam, Filippo de Marinis, Pierfrancesco Tassone, Amelia Insa Molla, Antonio Calles Blanco, Martin Emilio Lazaro Quintela, Enriqueta Felip Font, Anne-Marie Dingemans, Lynne Bui
Publikováno v:
The Lancet Respiratory Medicine. 8:1132-1143
Summary Background We evaluated the efficacy and safety of tepotinib, a potent and highly selective oral MET inhibitor, plus gefitinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) with MET overexp
Autor:
Carlo Putzu, Filippo de Marinis, Laura Bonanno, Sara Pilotto, Antonio Passaro, Lorenza Landi, Carlo Genova, Danilo Rocco, Rita Chiari, Luca Toschi, Chiara Bennati, Arsela Prelaj, Diego Cortinovis, Andrea Camerini, Marcello Tiseo, Claudia Proto, Federico Cappuzzo, Claudio Sini, Alessandro Tuzi, Giulio Cerea, Gianluca Spitaleri
Publikováno v:
Clinical Lung Cancer. 20:e186-e194
Background Molecular characterization of non–small-cell lung cancer (NSCLC), defined predictive and druggable mutations that greatly modified patient prognoses. The most frequent driver mutations detected in NSCLC are epidermal growth factor recept
Autor:
Cesare Gridelli, Filippo de Marinis, Vito Barbieri, Maria Rita Migliorino, Massimo Barberis, Fabiana Vitiello, Giampiero Romano, Stefano Gasparini, Alfonso Marchianò, Francesca Spinnato
Publikováno v:
Expert Review of Respiratory Medicine. 13:217-228
In the era of personalized cancer therapy, the sampling of adequate tumor tissue for histologic diagnosis and genomic profiling is crucial, not only at the initial diagnosis but also in the event of resistant and recurrent disease when sequential bio
Autor:
Maximilian Hochmair, A. Poltoratskiy, Michael Schumacher, Rafal Dziadziuszko, Silvia Novello, Konstantin Laktionov, Inna Egorova, Maria Rita Migliorino, Filippo de Marinis, W. Tang, Daphne Tsoi, Simona Rizzato, Gyula Ostoros, Antonio Passaro, L. Clementi, Agnieszka Cseh, Guzel Z Mukhametshina, Giulio Metro, Dariusz M. Kowalski, Maya Gottfried
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 152
Objectives Randomized controlled trials have demonstrated that afatinib is a suitable treatment option for patients with epidermal growth factor receptor mutation-positive (EGFRm +) non-small cell lung cancer (NSCLC). However, such studies often excl
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 16(5)
The first-line treatment of choice for patients with EGFR mutation-positive NSCLC is an EGFR tyrosine kinase inhibitor (TKI), of which five as follows are predominantly available in practice: gefitinib, erlotinib, afatinib, dacomitinib, and osimertin
Publikováno v:
Clinical lung cancer. 21(5)
Autor:
Antonio Rossi, Francesco Perrone, Filippo de Marinis, Fortunato Ciardiello, Agnese Montanino, Cesare Gridelli, Floriana Morgillo, Nicola Normanno, Ciro Gallo, Gennaro Daniele, Lucio Crinò, Maria Carmela Piccirillo, Alessandro Morabito
Publikováno v:
Clinical Lung Cancer. 17:461-465
BACKGROUND: About 20% of advanced non-small-cell lung cancer (NSCLC) cases harbor somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene. In these patients, the standard first-line treatments are the EGFR-
Autor:
Elena Guerini-Rocco, Caterina Fumagalli, Massimo Barberis, Filippo de Marinis, Davide Vacirca, Antonio Passaro
Publikováno v:
Immunotherapy. 10(12)